{"success":true,"data":{"pressRelease":{"id":"167430","rtpr_id":"nGNE6dRx9K-20261013","ticker":"MLAB","exchange":"NASDAQ","all_tickers":["MLAB"],"title":"Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth","author":"Globe Newswire","published_at":"2026-10-13T12:00:00.873Z","article_body":"The Restructuring Program focuses Clinical Genomics on profitability and adds\nresources in Sterilization and Disinfection Control, Calibration Solutions and\nAsia\n\nLAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc.\n(NASDAQ: MLAB) (“Mesa,” “we,” “us” or “our”), a global leader\nin the design and manufacture of critical quality control solutions and life\nsciences tools, today announced a savings plan (the “Savings Plan”)\nexpected to reduce annualized operating costs by approximately $9.3 million.\nThe Savings Plan consists of a global restructuring program (the\n\"Restructuring Program\"), a reduction in our San Diego, California facility\nfootprint and reduced third-party spending. We plan to reinvest approximately\n$4.3 million of the savings into the business to drive profitable growth, for\na net annualized cost reduction of approximately $5.0 million.\n\nThe Restructuring Program is designed to allocate resources toward\nopportunities that we expect to expand future profitability and create\nlong-term value for our shareholders. As part of the Restructuring Program, we\nwill eliminate approximately 40 positions, or approximately 6% of Mesa’s\ntotal employee base, with limited impact on manufacturing operations.\n\nThe cost reductions are concentrated primarily in our Clinical Genomics\ndivision, with additional reductions in corporate functions. We will reinvest\na portion of the savings in selected growth and infrastructure priorities,\nincluding adding business development capacity in Calibration Solutions,\ncommercial resources primarily in Asia, and key corporate positions. We expect\nthese investments to support more profitable growth.\n\n“Mesa is a set of durable, regulation-embedded franchises with real and\ngrowing earnings power, and fixable execution problems we have already begun\nto fix,” said Dr. Siddhartha Kadia, President and Chief Executive Officer.\n“My focus is disciplined execution and consistent, profitable growth across\nour four divisions.\n\n“As I said on our first quarter call, we are managing Clinical Genomics\ndeliberately, with full attention to its cost structure and returns. Following\nthe business reviews I have completed over my first six months, we are\nmanaging it for profitability, not for scale. These were difficult decisions,\nand we approached each one with care and respect for our team members. At the\nsame time, we have a responsibility to position the business for sustainable,\nprofitable growth.\n\n“This is not a broad cost reduction. It follows a decision about which\ncustomers Clinical Genomics is built to serve. We are focusing Clinical\nGenomics on pharmacogenomics and oncology, on customer accounts that use the\ninstrument at scale, and we are sizing the organization for that. This is not\na decision to pull back from specific regions; if an account uses the\ninstrument at scale, we want to serve it wherever it is. Revenue will be lower\nas a result, but we expect profitability to be meaningfully higher as the cost\ncomes out, and gross profit percentage to improve, because the revenue we are\nstepping away from is the lowest-margin revenue we have in Clinical Genomics.\nWe are also redirecting resources to accelerate standard product launches, the\nfastest-growing part of the Clinical Genomics portfolio. Our obligation is to\nmake every business in this portfolio earn its cost of capital, and we will\nreport against that standard.”\n\nADDING RESOURCES IN ASIA\n\nWe are adding commercial and technical resources in Asia for Sterilization and\nDisinfection Control and Biopharmaceutical Development, including a leader for\nAsia outside of China. These investments better align our resources with the\nbusinesses that generate most of our revenue in the region but have\nhistorically received a relatively small share of our resources there, and we\nexpect them to drive profitable growth in the region over time.\n\nFINANCIAL IMPACT\n\nThe Restructuring Program consists primarily of workforce reductions and, to a\nlesser extent, consolidation of the Clinical Genomics facility footprint,\nincluding exiting our Hamburg, Germany facility when its lease expires in\nFebruary 2027. Actions began after Board approval, and we expect them to be\nsubstantially complete by the end of fiscal year 2027, except for certain\ninternational employee exits with protected notice periods, which we expect to\ncomplete in the first half of fiscal year 2028.\n\nWe estimate that the Restructuring Program will result in total pre-tax\ncharges of approximately $2.6 million to $3.4 million, primarily during the\nsecond half of fiscal year 2027. These charges are expected to consist\nprimarily of employee-related costs of approximately $2.3 million to $3.0\nmillion, net of an expected non-cash reversal of approximately $0.3 million of\npreviously recognized stock-based compensation expense, and other exit costs,\nincluding third-party costs to administer these exits, of approximately $0.3\nmillion to $0.4 million. We expect related cash expenditures of approximately\n$2.9 million to $3.7 million, substantially all of which will occur over the\nnext 12 months.\n\nWe expect the Savings Plan to be fully reflected in our annualized cost\nstructure by the end of fiscal year 2028, at a net annualized cost reduction\nof approximately $5.0 million after the reinvestment described above. These\nfigures reflect cost reductions only; they exclude the expected decrease in\nClinical Genomics revenue and increase in its gross profit percentage\ndescribed above.\n\nWe will report second quarter fiscal year 2027 results on November 9, 2026,\nwhen we will also provide company-level fiscal year 2027 guidance that\nreflects the Savings Plan and the expected decrease in Clinical Genomics\nrevenue.\n\nABOUT MESA LABORATORIES\n\nMesa is a global leader in the design and manufacture of critical quality\ncontrol solutions and life sciences tools for regulated applications in the\npharmaceutical, healthcare and medical device industries. With manufacturing\noperations in the United States and Europe, and commercial reach across North\nAmerica, Europe, the Asia Pacific Region, and throughout the world, we serve\ncustomers whose applications demand accuracy, reliability and regulatory\ncompliance.\n\nFORWARD-LOOKING STATEMENTS\n\nCertain statements in this press release, such as statements relating to our\nestimates of annualized cost reductions, reinvestment, net annualized cost\nreduction, positions to be eliminated, pre-tax charges and related cash\nexpenditures as a result of the Restructuring Program; the expected effects of\nthe Savings Plan and the Restructuring Program on Clinical Genomics revenue\nand profitability, and the timeline for completion; and our expected reporting\ndate and plans to provide fiscal year 2027 guidance, may be considered\nforward-looking statements within the meaning of the U.S. Private Securities\nLitigation Reform Act of 1995. Forward-looking statements include those\npreceded by, followed by or that include the words \"will,\" \"may,\" \"could,\"\n\"would,\" \"should,\" \"believe,\" \"expect,\" \"anticipate,\" \"plan,\" \"estimate,\"\n\"target,\" \"project,\" \"intend\" or similar expressions. Such forward-looking\nstatements are subject to risks, uncertainties and other factors which could\ncause actual results to differ materially from historical experience or from\nfuture results expressed or implied by such forward-looking statements.\nPotential risks and uncertainties include, but are not limited to, the timing\nand outcome of required employee consultation and notice processes in certain\njurisdictions, the disruption of ongoing business, customer reactions to our\nnarrower commercial focus in Clinical Genomics, our ability to recruit for new\npositions, our ability to achieve the expected benefits of the Restructuring\nProgram, and other factors which can be found in our filings with the U.S.\nSecurities and Exchange Commission, including our Annual Report on Form 10-K\nfor the fiscal year ended March 31, 2026. Any forward-looking statement speaks\nonly as of the date on which it is made. We do not undertake or assume any\nobligation to update or revise any forward-looking statement, whether as a\nresult of new information, future events or otherwise, except as required by\nlaw.\n\nCONTACTS\nMesa Laboratories Contacts: John Sakys; CFO\n1-303-987-8000\ninvestorrelations@mesalabs.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE6dRx9K-20261013","title":"Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth","author":"Globe Newswire","ticker":"MLAB","created":"2026-10-13T12:00:00.873Z","tickers":["MLAB"],"exchange":"NASDAQ","article_body":"The Restructuring Program focuses Clinical Genomics on profitability and adds\nresources in Sterilization and Disinfection Control, Calibration Solutions and\nAsia\n\nLAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc.\n(NASDAQ: MLAB) (“Mesa,” “we,” “us” or “our”), a global leader\nin the design and manufacture of critical quality control solutions and life\nsciences tools, today announced a savings plan (the “Savings Plan”)\nexpected to reduce annualized operating costs by approximately $9.3 million.\nThe Savings Plan consists of a global restructuring program (the\n\"Restructuring Program\"), a reduction in our San Diego, California facility\nfootprint and reduced third-party spending. We plan to reinvest approximately\n$4.3 million of the savings into the business to drive profitable growth, for\na net annualized cost reduction of approximately $5.0 million.\n\nThe Restructuring Program is designed to allocate resources toward\nopportunities that we expect to expand future profitability and create\nlong-term value for our shareholders. As part of the Restructuring Program, we\nwill eliminate approximately 40 positions, or approximately 6% of Mesa’s\ntotal employee base, with limited impact on manufacturing operations.\n\nThe cost reductions are concentrated primarily in our Clinical Genomics\ndivision, with additional reductions in corporate functions. We will reinvest\na portion of the savings in selected growth and infrastructure priorities,\nincluding adding business development capacity in Calibration Solutions,\ncommercial resources primarily in Asia, and key corporate positions. We expect\nthese investments to support more profitable growth.\n\n“Mesa is a set of durable, regulation-embedded franchises with real and\ngrowing earnings power, and fixable execution problems we have already begun\nto fix,” said Dr. Siddhartha Kadia, President and Chief Executive Officer.\n“My focus is disciplined execution and consistent, profitable growth across\nour four divisions.\n\n“As I said on our first quarter call, we are managing Clinical Genomics\ndeliberately, with full attention to its cost structure and returns. Following\nthe business reviews I have completed over my first six months, we are\nmanaging it for profitability, not for scale. These were difficult decisions,\nand we approached each one with care and respect for our team members. At the\nsame time, we have a responsibility to position the business for sustainable,\nprofitable growth.\n\n“This is not a broad cost reduction. It follows a decision about which\ncustomers Clinical Genomics is built to serve. We are focusing Clinical\nGenomics on pharmacogenomics and oncology, on customer accounts that use the\ninstrument at scale, and we are sizing the organization for that. This is not\na decision to pull back from specific regions; if an account uses the\ninstrument at scale, we want to serve it wherever it is. Revenue will be lower\nas a result, but we expect profitability to be meaningfully higher as the cost\ncomes out, and gross profit percentage to improve, because the revenue we are\nstepping away from is the lowest-margin revenue we have in Clinical Genomics.\nWe are also redirecting resources to accelerate standard product launches, the\nfastest-growing part of the Clinical Genomics portfolio. Our obligation is to\nmake every business in this portfolio earn its cost of capital, and we will\nreport against that standard.”\n\nADDING RESOURCES IN ASIA\n\nWe are adding commercial and technical resources in Asia for Sterilization and\nDisinfection Control and Biopharmaceutical Development, including a leader for\nAsia outside of China. These investments better align our resources with the\nbusinesses that generate most of our revenue in the region but have\nhistorically received a relatively small share of our resources there, and we\nexpect them to drive profitable growth in the region over time.\n\nFINANCIAL IMPACT\n\nThe Restructuring Program consists primarily of workforce reductions and, to a\nlesser extent, consolidation of the Clinical Genomics facility footprint,\nincluding exiting our Hamburg, Germany facility when its lease expires in\nFebruary 2027. Actions began after Board approval, and we expect them to be\nsubstantially complete by the end of fiscal year 2027, except for certain\ninternational employee exits with protected notice periods, which we expect to\ncomplete in the first half of fiscal year 2028.\n\nWe estimate that the Restructuring Program will result in total pre-tax\ncharges of approximately $2.6 million to $3.4 million, primarily during the\nsecond half of fiscal year 2027. These charges are expected to consist\nprimarily of employee-related costs of approximately $2.3 million to $3.0\nmillion, net of an expected non-cash reversal of approximately $0.3 million of\npreviously recognized stock-based compensation expense, and other exit costs,\nincluding third-party costs to administer these exits, of approximately $0.3\nmillion to $0.4 million. We expect related cash expenditures of approximately\n$2.9 million to $3.7 million, substantially all of which will occur over the\nnext 12 months.\n\nWe expect the Savings Plan to be fully reflected in our annualized cost\nstructure by the end of fiscal year 2028, at a net annualized cost reduction\nof approximately $5.0 million after the reinvestment described above. These\nfigures reflect cost reductions only; they exclude the expected decrease in\nClinical Genomics revenue and increase in its gross profit percentage\ndescribed above.\n\nWe will report second quarter fiscal year 2027 results on November 9, 2026,\nwhen we will also provide company-level fiscal year 2027 guidance that\nreflects the Savings Plan and the expected decrease in Clinical Genomics\nrevenue.\n\nABOUT MESA LABORATORIES\n\nMesa is a global leader in the design and manufacture of critical quality\ncontrol solutions and life sciences tools for regulated applications in the\npharmaceutical, healthcare and medical device industries. With manufacturing\noperations in the United States and Europe, and commercial reach across North\nAmerica, Europe, the Asia Pacific Region, and throughout the world, we serve\ncustomers whose applications demand accuracy, reliability and regulatory\ncompliance.\n\nFORWARD-LOOKING STATEMENTS\n\nCertain statements in this press release, such as statements relating to our\nestimates of annualized cost reductions, reinvestment, net annualized cost\nreduction, positions to be eliminated, pre-tax charges and related cash\nexpenditures as a result of the Restructuring Program; the expected effects of\nthe Savings Plan and the Restructuring Program on Clinical Genomics revenue\nand profitability, and the timeline for completion; and our expected reporting\ndate and plans to provide fiscal year 2027 guidance, may be considered\nforward-looking statements within the meaning of the U.S. Private Securities\nLitigation Reform Act of 1995. Forward-looking statements include those\npreceded by, followed by or that include the words \"will,\" \"may,\" \"could,\"\n\"would,\" \"should,\" \"believe,\" \"expect,\" \"anticipate,\" \"plan,\" \"estimate,\"\n\"target,\" \"project,\" \"intend\" or similar expressions. Such forward-looking\nstatements are subject to risks, uncertainties and other factors which could\ncause actual results to differ materially from historical experience or from\nfuture results expressed or implied by such forward-looking statements.\nPotential risks and uncertainties include, but are not limited to, the timing\nand outcome of required employee consultation and notice processes in certain\njurisdictions, the disruption of ongoing business, customer reactions to our\nnarrower commercial focus in Clinical Genomics, our ability to recruit for new\npositions, our ability to achieve the expected benefits of the Restructuring\nProgram, and other factors which can be found in our filings with the U.S.\nSecurities and Exchange Commission, including our Annual Report on Form 10-K\nfor the fiscal year ended March 31, 2026. Any forward-looking statement speaks\nonly as of the date on which it is made. We do not undertake or assume any\nobligation to update or revise any forward-looking statement, whether as a\nresult of new information, future events or otherwise, except as required by\nlaw.\n\nCONTACTS\nMesa Laboratories Contacts: John Sakys; CFO\n1-303-987-8000\ninvestorrelations@mesalabs.com"},"type":"article","timestamp":"2026-10-13T12:00:01.131516412Z","server_sent_at_ms":1791892801131},"received_at":"2026-10-13T12:00:01.184Z","source_url":null},"analysis":{"id":"155738","press_release_id":"167430","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["company explicitly guides to lower Clinical Genomics revenue as a result of the restructuring","execution risk on achieving expected benefits; customer reaction to narrower commercial focus cited as a risk"],"eventType":"restructuring","narrative":"Mesa Laboratories announced a Savings Plan expected to reduce annualized operating costs by approximately $9.3 million, with $4.3 million reinvested for a net annualized reduction of approximately $5.0 million.\n\nThe Restructuring Program eliminates approximately 40 positions (about 6% of the workforce), concentrates cuts in the Clinical Genomics division, and includes exiting the Hamburg, Germany facility when its lease expires in February 2027.\n\nManagement explicitly guided that Clinical Genomics revenue will decline as the division refocuses on higher-margin pharmacogenomics and oncology accounts, with gross profit percentage expected to improve. Pre-tax charges are estimated at $2.6-3.4 million, mostly in the second half of fiscal 2027.\n\nFiscal 2027 guidance reflecting the Savings Plan will be provided with Q2 results on November 9, 2026.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"Margin-over-scale pivot in Clinical Genomics -- cost savings real, but a revenue give-up is coming; watch the November 9 guidance."},"keyFigures":{"customDimensions":{"reinvestment":"$4.3 million","pre_tax_charges":"$2.6 million to $3.4 million","other_exit_costs":"$0.3 million to $0.4 million","cash_expenditures":"$2.9 million to $3.7 million","stock_comp_reversal":"$0.3 million","positions_eliminated":"approximately 40","employee_related_costs":"$2.3 million to $3.0 million","q2_fy27_reporting_date":"November 9, 2026","workforce_reduction_pct":"approximately 6%","annualized_cost_reduction":"$9.3 million","net_annualized_cost_reduction":"$5.0 million"}},"quotedText":"Revenue will be lower as a result, but we expect profitability to be meaningfully higher as the cost comes out, and gross profit percentage to improve","namedEntities":{"people":[{"name":"Dr. Siddhartha Kadia","role":"President and Chief Executive Officer"},{"name":"John Sakys","role":"CFO"}],"products":[],"companies":[{"name":"Mesa Laboratories, Inc.","ticker":"MLAB","relationship":"filer"}],"dollarAmounts":[{"amount":"$9.3 million","context":"expected annualized operating cost reduction"},{"amount":"$4.3 million","context":"planned reinvestment into the business"},{"amount":"$5.0 million","context":"net annualized cost reduction"},{"amount":"$2.6 million to $3.4 million","context":"estimated total pre-tax restructuring charges"},{"amount":"$2.9 million to $3.7 million","context":"expected related cash expenditures over next 12 months"}]},"materialImpact":{"score":3,"reasoning":"A formal restructuring eliminating ~6% of the workforce with ~$5.0M net annualized cost savings and $2.6-3.4M in pre-tax charges is material for a small-cap life sciences tools company, but it is not an M&A, FDA, or earnings-surprise class event. The mixed tone reflects cost savings offset by an acknowledged revenue decline in Clinical Genomics."},"tickerRelevance":{"others":[],"primary":"MLAB"},"globalImportance":30,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"restructuring with disclosed charges and revenue trade-off","sectorWeight":"life sciences tools","issuerAuthored":true}},"event_type":"restructuring","event_type_secondary":null,"sentiment":"mixed","material_impact_score":3,"narrative":"Mesa Laboratories announced a Savings Plan expected to reduce annualized operating costs by approximately $9.3 million, with $4.3 million reinvested for a net annualized reduction of approximately $5.0 million.\n\nThe Restructuring Program eliminates approximately 40 positions (about 6% of the workforce), concentrates cuts in the Clinical Genomics division, and includes exiting the Hamburg, Germany facility when its lease expires in February 2027.\n\nManagement explicitly guided that Clinical Genomics revenue will decline as the division refocuses on higher-margin pharmacogenomics and oncology accounts, with gross profit percentage expected to improve. Pre-tax charges are estimated at $2.6-3.4 million, mostly in the second half of fiscal 2027.\n\nFiscal 2027 guidance reflecting the Savings Plan will be provided with Q2 results on November 9, 2026.","key_figures":{"customDimensions":{"reinvestment":"$4.3 million","pre_tax_charges":"$2.6 million to $3.4 million","other_exit_costs":"$0.3 million to $0.4 million","cash_expenditures":"$2.9 million to $3.7 million","stock_comp_reversal":"$0.3 million","positions_eliminated":"approximately 40","employee_related_costs":"$2.3 million to $3.0 million","q2_fy27_reporting_date":"November 9, 2026","workforce_reduction_pct":"approximately 6%","annualized_cost_reduction":"$9.3 million","net_annualized_cost_reduction":"$5.0 million"}},"named_entities":{"people":[{"name":"Dr. Siddhartha Kadia","role":"President and Chief Executive Officer"},{"name":"John Sakys","role":"CFO"}],"products":[],"companies":[{"name":"Mesa Laboratories, Inc.","ticker":"MLAB","relationship":"filer"}],"dollarAmounts":[{"amount":"$9.3 million","context":"expected annualized operating cost reduction"},{"amount":"$4.3 million","context":"planned reinvestment into the business"},{"amount":"$5.0 million","context":"net annualized cost reduction"},{"amount":"$2.6 million to $3.4 million","context":"estimated total pre-tax restructuring charges"},{"amount":"$2.9 million to $3.7 million","context":"expected related cash expenditures over next 12 months"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T12:00:17.064Z","global_importance":30,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"restructuring with disclosed charges and revenue trade-off","sectorWeight":"life sciences tools","issuerAuthored":true}},"durationMs":6786,"modelName":"glm-5.3-flashx"}}